[1]张岩基,王汇源,李浩,等.经导管动脉化疗栓塞和肝动脉灌注化疗治疗肝细胞癌现状和进展[J].介入放射学杂志,2024,33(09):1039-1044.
　ZHANG Yanji,WANG Huiyuan,LI Hao,et al.Current status and progress of TACE and HAIC in the treatment of hepatocellular carcinoma[J].journal interventional radiology,2024,33(09):1039-1044.
点击复制

经导管动脉化疗栓塞和肝动脉灌注化疗治疗肝细胞癌现状和进展()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
33
期数:
2024年09
页码:
1039-1044
栏目:
综述
出版日期:
2024-09-17

文章信息/Info

Title:
Current status and progress of TACE and HAIC in the treatment of hepatocellular carcinoma
作者:
张岩基; 王汇源; 李浩; 段旭华
Author(s):
ZHANG Yanji; WANG Huiyuan; LI Hao; DUAN Xuhua
Clinical Medical College of Zhengzhou University；Department of Interventional Radiology，First Affiliated Hospital of Zhengzhou University，Zhengzhou，Henan Province 450002，China
关键词:
【关键词】肝细胞癌; 经导管动脉化疗栓塞术; 肝动脉灌注化疗
文献标志码:
A
摘要:
【摘要】原发性肝癌是全球常见恶性肿瘤，在我国是第4位常见恶性肿瘤和第2位肿瘤致死病因。我国肝细胞癌（HCC）患者确诊时大多为中晚期，已无法接受根治性治疗。目前以经导管动脉化疗栓塞术（TACE）为主的局部治疗联合全身治疗已成为不可切除HCC主流治疗方案，而肝动脉灌注化疗（HAIC）作为一种新选择受到广泛关注。该文综述了TACE联合HAIC治疗HCC研究新进展，得出结论为TACE联合HAIC对不可切除的BCLC分期C期、巨块型HCC及门静脉受侵患者的疗效优于TACE，但对BCLC分期A/B期患者的疗效与TACE无明显差异。希望能为临床HCC患者治疗提供有效建议，并为进一步规范TACE及后期HAIC，设计相关临床研究提供依据。

参考文献/References:

［1］Sung H，Ferlay J，Siegel RL，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin，2021，71：209-249.
［2］Rumgay H，Arnold M，Ferlay J，et al. Global burden of primary liver cancer in 2020 and predictions to 2040［J］. J Hepatol，2022，77：1598-1606.
［3］Zheng R，Zhang S，Zeng H，et al. Cancer incidence and mortality in China，2016［J］. J Natl Cancer Center，2022，2：1-9.
［4］Zeng H，Chen W，Zheng R，et al. Changing cancer survival in China during 2003-15：a pooled analysis of 17 population-based cancer registries［J］. Lancet Glob Health，2018，6：e555-e567.
［5］Zhong JH，Peng NF，You XM，et al. Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China：a real-world study［J］. Oncotarget，2017，8：18296-18302.
［6］Terashima T，Yamashita T，Toyama T，et al. Surrogacy of time to progression for overall survival in advanced hepatocellular carcinoma treated with systemic therapy：a systematic review and meta-analysis of randomized controlled trials［J］. Liver Cancer，2019，8：130-139.
［7］Bruix J，Reig M，Sherman M. Evidence-based diagnosis，staging，and treatment of patients with hepatocellular carcinoma［J］. Gastroenterology，2016，150：835-853.
［8］中华人民共和国国家卫生健康委员会.原发性肝癌诊疗指南（2022年版）［J］.肿瘤综合治疗电子杂志，2022，8：16-53.
［9］中国医师协会介入医师分会临床诊疗指南专委会.中国肝细胞癌经动脉化疗栓塞（TACE）治疗临床实践指南（2021年版）［J］.中华医学杂志，2021，101：1848-1862.
［10］Morimoto M，Numata K，Kondou M，et al. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma：a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization［J］. Cancer，2010，116：5452-5460.
［11］Liu C，Li T，He JT，et al. TACE combined with microwave ablation therapy vs. TACE alone for treatment of early-and intermediate-stagehepatocellular carcinomas larger than 5 cm：a meta-analysis［J］. Diagn Interv Radiol，2020，26：575-583.
［12］Masatoshi K，Kazuomi U，Masafumi I，et al.Randomised，multicentre prospective trial of transarterial chemoembolisation（TACE）plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma：TACTICS trial.［J］.Gut，2020，69：1492-1501.
［13］Lee TY，Lin CC，Chen CY，et al. Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early intermediate stage hepatocellular carcinoma：a post hoc analysis of the START trial［J］. Medicine（Baltimore），2017，96：e7655.
［14］Li Z，Zhou JX，Ren JZ，et al. Clinical value of iodine［131I］metuximab infusion combined with TACE for treatment of patients with post-intervention relapse of mid or advanced stage hepatocellular carcinoma［J］. Zhonghua Gan Zang Bing Za Zhi，2013，21：728-733.
［15］中国抗癌协会肝癌专业委员会.肝动脉灌注化疗治疗肝细胞癌中国专家共识（2021版）［J］.中华消化外科杂志，2021，20：754-759.
［16］李蓓，孙庆敏，黄磊.注射用亚叶酸钙与亚叶酸钠的临床应用及分析［J］.现代医药卫生，2015，31：64-66.
［17］李榕，李文利，胡晓云，等.RALOX-HAIC联合免疫检查点抑制剂及靶向药物治疗中晚期肝癌的疗效分析［J］.中国肿瘤临床，2023，50：555-560.
［18］He M，Li Q，Zou R，et al. Sorafenib plus hepatic arterial infusion of oxaliplatin，fluorouracil，and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion：a randomized clinical trial［J］. JAMA Oncol，2019，5：953-960.
［19］Lyu N，Wang X，Li JB，et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma：a biomolecular exploratory，randomized，phase Ⅲ trial（FOHAIC-1）［J］. J Clin Oncol，2022，40：468-480.
［20］Li QJ，He MK，Chen HW，et al. Hepatic arterial infusion ofoxaliplatin，fluorouracil，and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma：a randomized phase Ⅲ trial［J］. J Clin Oncol，2022，40：150-160.
［21］邓海辉.D-TACE联合HAIC治疗大或巨大肝癌的疗效与安全性研究［D］.广东：广州医科大学，2022.
［22］高嵩，朱旭，杨仁杰，等.TACE联合奥沙利铂、氟尿嘧啶、亚叶酸钙肝动脉化疗治疗中晚期原发性肝癌［J］.介入放射学杂志，2012，21：377-383.
［23］Gao S，Zhang P，Guo J，et al. Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients［J］. World J Gastroenterol，2015，21：10443-10452.
［24］Guo W，Gao J，Zhuang W，et al. Efficacy and safety of hepatic arterial infusion chemotherapy combined with transarterial embolization for unresectable hepatocellular carcinoma：a propensity score-matching cohort study［J］. JGH Open，2020，4：477-483.
［25］Huang J，Huang W，Zhan M，et al. Drug-eluting bead transarterial chemoembolization combined with FOLFOX-based hepatic arterial infusion chemotherapy for large or huge hepatocellular carcinoma［J］. J Hepatocell Carcinoma，2021，8：1445-1458.
［26］Li B，Qiu L，Zheng Y，et al. Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma［J］. Ann Surg Open，2021，2：e057.
［27］Liu BJ，Gao S，Zhu X，et al. Combination therapy of chemoembolization and hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis compared with chemoembolization alone：a propensity score-matched analysis［J］. Biomed Res Int，2021，2021：6670367.
［28］Zhu L，Xu S，Qian H. Transarterial embolization and low-dose continuous hepatic arterial infusion chemotherapy with oxaliplatin and raltitrexed for hepatocellular carcinoma with major portal vein tumor thrombus［J］. World J Gastroenterol，2018，24：2501-2507.
［29］Li JH，Xie XY，Zhang L，et al. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma［J］. World J Gastroenterol，2015，21：3970-3977.
［30］Hsu CH，Yang TS，Hsu C，et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma［J］. Br J Cancer，2010，102：981-986.
［31］Niu ZJ，Ma YL，Kang P，et al. Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus：using a new classification［J］. Med Oncol，2012，29：2992-2997.
［32］Ge N，Wang H，He C，et al. Optimal interventional treatment for liver cancer：HAIC，TACE or iTACE?［J］. J Interv Med，2023，6：59-63.

相似文献/References:

[1]黄渊全,贾中芝,冯耀良,等.CT灌注成像在肝癌TACE术后疗效评价中的应用价值[J].介入放射学杂志,2009,(06):437.
　HUANG Yuan-quan,JIA Zhong-zhi,FENG Yao-liang,et al.Clinical application of CT perfusion imaging in estimating the efficacy of transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma[J].journal interventional radiology,2009,(09):437.
[2]王有枝,李彦豪,梅雀林,等.原发性肝癌肝动脉化疗栓塞术后继发溶血性尿毒综合征3例并文献复习[J].介入放射学杂志,2016,(06):543.
　WANG You-zhi,LI Yan-hao,MEI Que-lin,et al.Secondary hemolytic uremic syndrome occurring after transcatheter arterial chemoembolization for primary hepatocellular carcinoma: report of 3 cases with literature review [J].journal interventional radiology,2016,(09):543.
[3]陈成,沈艳峰,董云,等.阿帕替尼联合TACE治疗原发性肝癌有效性和安全性meta分析 [J].介入放射学杂志,2020,29(03):251.
　CHEN Cheng,SHEN Yanfeng,DONG Yun,et al.Apatinib combined with TACE for primary liver cancer: a meta-analysis of its effectiveness and safety[J].journal interventional radiology,2020,29(09):251.
[4]于清泳,赵 辉.结直肠癌肝转移患者TACE治疗后含表皮生长因子的纤维蛋白样细胞外基质2水平及意义 [J].介入放射学杂志,2021,30(10):1035.
　YU Qingyong,ZHAO Hui..The level and significance of EGF containing fibulin-like extracellular matrix protein 2 in patients with liver metastases from colorectal cancer after TACE treatment[J].journal interventional radiology,2021,30(09):1035.
[5]蒋健强,李晓娟,李拥军,等.白蛋白-胆红素评分在预测TACE治疗巨块型肝细胞癌后肝功能衰竭中的应用[J].介入放射学杂志,2023,32(01):55.
　JIANG Jianqiang,LI Xiaojuan,LI Yongjun,et al.The application of albumin-bilirubin score in predicting liver failure after transarterial chemoembolization for massive hepatocellular carcinoma [J].journal interventional radiology,2023,32(09):55.
[6]刘　晟,周平盛,沈　强,等.超声引导下微波消融术治疗特殊部位与非特殊部位单发肝细胞癌的疗效对比[J].介入放射学杂志,2023,32(01):36.
　LIU Sheng,ZHOU Pingsheng,SHEN Qiang,et al.Ultrasound-guided microwave ablation for the treatment of single hepatocellular carcinoma located at specific area and at non-specific area: comparison of clinical efficacy[J].journal interventional radiology,2023,32(09):36.
[7]王　曦,冯　苏,李　红,等.免疫检查点抑制剂联合TACE在肝癌治疗中的研究进展[J].介入放射学杂志,2023,32(01):90.
　WANG Xi,FENG Su,LI Hong,et al.Research progress in immune checkpoint inhibitors combined with TACE for the treatment of hepatocellular carcinoma[J].journal interventional radiology,2023,32(09):90.
[8]秦焕蓉,程芝梅,吴祥锴,等.经导管动脉化疗栓塞和微波消融治疗VX2肝癌诱导低氧诱导因子-1α调节糖酵解与微血管密度相关性分析研究[J].介入放射学杂志,2024,33(04):390.
　QIN Huanrong,CHENG Zhimei,WU Xiangkai,et al.Correlation between HIF-1α regulation of glycolysis and microvessel density induced by transcatheter arterial chemoembolization and microwave ablation in experimental rabbits with VX2 hepatocellular carcinoma[J].journal interventional radiology,2024,33(09):390.
[9]吴迪,郑琳.载药微球栓塞治疗在肝癌全程管理中的临床应用进展[J].介入放射学杂志,2024,33(08):921.
　WU Di,ZHENG Lin..Application progress of drug-loaded microspheres embolization therapy in the clinical full-process management of hepatocellular carcinoma[J].journal interventional radiology,2024,33(09):921.
[10]陈荔,吴大广,朱光宇,等.经动脉化疗栓塞联合免疫和靶向药治疗Child-Pugh B级肝细胞癌研究[J].介入放射学杂志,2024,33(09):968.
　CHEN Li,WU Daguang,ZHU Guangyu,et al.Transarterial chemoembolization combined with immune checkpoint inhibitor and molecular targeted therapy for Child-Pugh grade B hepatocellular carcinoma[J].journal interventional radiology,2024,33(09):968.
[11]杜楠,王英,李文涛.肝癌TACE还是HAIC？[J].介入放射学杂志,2024,33(12):1269.
　DU Nan,WANG Ying,LI Wentao..Treatment of hepatocellular carcinoma：TACE or HAIC？[J].journal interventional radiology,2024,33(09):1269.
[12]张赛锋,王道仁,邵国良.小粒径载药微球在肝细胞癌治疗中的安全性和疗效分析[J].介入放射学杂志,2024,33(12):1373.
　ZHANG Saifeng,WANG Daoren,SHAO Guoliang..Small-size drug-eluting beads TACE for the treatment of hepatocellular carcinoma：its safety and efficacy analysis[J].journal interventional radiology,2024,33(09):1373.

备注/Memo

备注/Memo:
（收稿日期：2023-09-18）（本文编辑：谷珂）
更新日期/Last Update: 2024-09-16